Field Based: West
Are you ready to join a team committed to making a meaningful impact on cancer treatment through the discovery and development of precision medicines? At Kura Oncology, you have an opportunity to be a part of something bigger, with a lasting impact that you can be proud of.
At Kura Oncology, we are working to change the paradigm and improve the science of cancer treatment. As an organization, we strive to cultivate a diverse and talented professional culture driven to develop precision medicine therapeutics.
This role is a field based, non-promotional medical and scientific role. The MSL's key objective is to engage scientifically with HCPs and medical experts in support of Kura's corporate and medical strategies and plans. The ideal MSL has had experience in AML, HNSCC, or NSCLC and has prior or existing relationships with experts in these areas. The MSL will also collaborate regularly and effectively with cross-functional colleagues.
ESSENTIAL JOB FUNCTIONS:Establish and maintain scientific relationships with national, regional, and local opinion leaders in addition to other healthcare providers.Engage in meaningful, peer-to-peer scientific exchange of medical and scientific information with the oncology and hematology community, consistent with the integrated Medical Affairs Plan (iMAP).Provide internal stakeholders with feedback and insights from interactions and discussions with HCPs.Explore potential new areas of interest to understand unmet needs, how the landscape is evolving, and how Kura pipeline products could address an unmet need.Collaborate with clinical development / operations to identify clinical trial sites / investigators and to enhance patient enrollment in Kura sponsored clinical trials.Keep abreast of medical and scientific developments in the designated disease areas by continuously reviewing literature in the field, monitoring competitor activities, networking with experts and attending relevant conferences.Deliver approved medical/scientific presentations to internal & external stakeholders.Facilitation of investigator-sponsored trials (ISTs)Lead the planning and execution of subject matter expert meetings/advisory boards, aligned with the Global Medical Affairs strategy.Collaborate with cross functional partners on internal projects and external initiatives/projects, consistent with the iMAP.Support medical/scientific training of cross functional teams and contribute in external medical education.Adhere to corporate and healthcare compliance guidance in all activities, including those related to clinical trials, scientific interactions with internal and external groups, and responses to unsolicited requests for medical/scientific information.JOB SPECIFICATIONS:PharmD, PhD, or MD preferred, Advanced degree nurses, NPs, PAs, or those with a master's degree in life sciences with clinical research experience may also apply5+ years of experience in the biotech or pharmaceutical industry in Global or US Medical AffairsOncology /Hematology experience with established relationships with key opinion leaders in therapeutic areas of interestStrong interpersonal, presentation and communication skills and demonstrated ability to work collaboratively in a dynamic, team-oriented environmentDemonstrated self-starter and team player with strong interpersonal skills.Ability to interpret key scientific data and translate findings to meet educational and research needsAble to ensure compliance with corporate rules and government regulationsTravel is required as part of this positionThe base range for a Senior MSL is $234,417 - $256,805 per year. Individual pay may vary based on additional factors, including, and without limitation, job-related skills, experience, work location, and relevant education or training. Kura's compensation package also includes generous benefits, equity, and participation in an annual target bonus. Kura's Values that are used for candidate selection and performance assessments: We work as one for patientsWe are goal-focused and deliver with excellenceWe are science-driven courageous innovatorsWe strive to bring out the best in each other and ourselvesThe Kura Package Competitive comp packageBonus401K + Employer contributionsGenerous stock optionsESPP Plan20 days of PTO to start18 Holidays (Including Summer & Winter Break)Generous Benefits Package with a variety of plans available with a substantial employer matchPaid Paternity/Maternity LeaveIn-Office Catered lunchesHome Office SetupLifestyle Spending StipendCommuter Stipend (Boston Office)Regular employee social activities, including happy hours, monthly birthday celebrations, Kura Koffee Talks, and much more!Kura Oncology is a clinical-stage biopharmaceutical company discovering and developing personalized therapeutics for the treatment of blood cancers and solid tumors. The company's diverse pipeline consists of small molecules that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura Oncology's approach to drug development is focused on rapidly translating novel science into life-saving medicines. Our goal is to help patients with cancer lead better, longer lives. Kura Oncology has offices in San Diego, California, and Boston, Massachusetts.
Kura's pipeline consists of three investigational drug candidates: ziftomenib, tipifarnib and KO-2806. Ziftomenib, a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction, has received Breakthrough Therapy Designation for the treatment of R/R NPM1-mutant acute myeloid leukemia (AML). Kura has completed enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML (KOMET-001). The Company is also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. Tipifarnib, a potent and selective farnesyl transferase inhibitor (FTI), is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma (KURRENT-HN). Kura is also evaluating KO-2806, a next-generation FTI, in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies (FIT-001). For additional information, please visit Kura's website at www.kuraoncology.com and follow us on X and LinkedIn.
Kura Oncology is committed to creating a diverse environment and is proud to be an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, age, or veteran status.
#J-18808-Ljbffr